Policy Analysis: Life Sciences, Policy
Published:

EU’S Innovative Medicines Initiative to collaborate with FDA’s Critical Path

US/European move to put more weight behind moves to improve drug development processes and increase’s R&D productivity in the pharmaceutical industry

Image: Bigstock

Europe’s Innovative Medicines Initiative (IMI) is joining forces with its US counterpart, the Critical Path Institute (C-Path) to further their shared mission of reshaping the drug development process to improve the productivity of pharmaceutical industry R&D.

Both organisations bring together scientists from the industry and academic institutions, with representatives from patient organisations, small companies and regulatory agencies, in precompetitive public-private partnerships.

By combining knowledge and expertise, these partnerships aim to tackle challenges that are too big and complex...



Related subjects: EU, USA

Views of 2030: Transport, manufacturing, education and health
In October 2014, members of the Science|Business Network of universities and companies met in Berlin to compare notes about the future of four key sectors in Europe. This is what they see coming.